Leheny A. Rachel 4

What Happened Leheny A. Rachel, CEO of CalciMedica, acquired 186,729 shares on June 25, 2026 at $0.80 per share for a total of $149,999. The transaction is reported as an "A" (grant, award or other acquisition) and the shares were issued by the company pursuant to a Securities Purchase Agreement dated June 23, 2026 with a closing on June 25, 2026; the issuance was approved by an independent committee of the Board.

Key Details

• Transaction date & price: June 25, 2026 — 186,729 shares at $0.80 per share; total $149,999.
• Transaction type: "A" (award/acquisition) from the issuer under a Securities Purchase Agreement (see footnote F1).
• Shares owned after transaction: Not specified in the provided filing.
• Footnote F1: Securities were acquired under a June 23, 2026 SPA; closing June 25, 2026; issuance approved by an independent board committee.
• Footnote F2: Rachel is a co‑founder/managing director of Valence IV, V and VI and may be deemed to beneficially own shares held by those SPVs; she disclaims beneficial ownership except for her pecuniary interest.
• Filing date: Form 4 filed June 29, 2026 — appears timely (filed within the SEC’s two-business-day window for Form 4s).

Context This was an issuer-side acquisition (company-issued shares) rather than an open-market purchase or sale. For retail investors, purchases or acquisitions by executives can be informative, but this is a relatively modest ($150k) issuance and may reflect financing/transactional arrangements rather than a personal open-market investment. The footnote about Valence SPVs indicates potential indirect ownership interests separate from this issuance.